Latest news
Charles River Laboratories and ENYO Pharma today announced results of a successful collaboration
(http://ir.criver.com/phoenix.zhtml?c=121668&p=irol-newsArticle&ID=2318801)
Initiation of a collaboration with Paris-Diderot University to discover new drugs against adenoviruses
ENYO Pharma announces its collaboration with Paris-Diderot University, Inserm Unit U941 (Institut Universitaire d’Hématologie), leaded by IDF Innov SATT, to discover new drugs against adenoviruses. The collaboration, built upon ENYO Pharma’s unique approach inspired by viruses, will identify new human cellular targets and pathway essential for replication of adenoviruses. This information will help to select experimental or clinical-stage small molecules that will be tested in a drug repositioning strategy. ENYO pharma will provide its peptide and small molecule libraries to the University team which will screen and analyse their impact on adenoviruses’
ENYO Pharma pursues its international strategy and opens a new subsidiary in Australia
ENYO Pharma has opened its first wholly owned subsidiary in Australia. This office will be our new center to manage clinical trials in the Asia-Pacific region. ENYO Pharma has based its innovation on mimicking virus strategies to discover new cellular targets and develop drug candidates in infectious diseases and beyond.
MIMESIS Newsletter #1: a novel systems biology approach to develop preclinical assets
MIMESIS NEWSLETTER #1, April 2017
A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses.
MIMESIS is a research and innovation project coordinated by ENYO Pharma and funded under the highly selective H2020 – SMEInstrument – Phase 2 call that aims at: “Dedicated support to biotechnology SMEs closing the gap from lab to market”. The MIMESIS project was launched on Nov 2016 for 2 years.
A new collaboration studying the impact of FXR function on HBV replications
ENYO Pharma is pleased to announce the initiation of a collaboration with the group of Professor Patrice André (Inserm U1111, Lyon, France) to develop a deeper understanding of how FXR agonists inhibit the replication cycle of Hepatitis B (HBV). In addition to identifying opportunities for new anti-HBV therapeutics, this collaboration will strengthen understanding of the mode of action of EYP001, ENYO’s lead compound. EYP001 is a highly selective FXR modulator that reduces the HBV cccDNA reservoir,
Latest Press Release 